# Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I

> **NCT01040130** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 151 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Olodaterol (BI 1744)
- **DRUG:** Olodaterol (BI 1744)
- **DRUG:** Placebo
- **DRUG:** Olodaterol (BI 1744)
- **DRUG:** Olodaterol (BI 1744) Placebo

## Key facts

- **NCT ID:** NCT01040130
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2011-04
- **Final completion:** —
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2014-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01040130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01040130, "Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01040130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*